[Skip to Content]
[Skip to Content Landing]

Year

Day

October 17, 2019
Original Investigation

Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer

Abstract Full Text
JAMA Oncol. Published online October 17, 2019. doi:10.1001/jamaoncol.2019.3616

This multicenter cohort study assesses whether serial postsurgical and postchemotherapy analyses of circulating tumor DNA levels could provide a real-time indication of adjuvant therapy efficacy in patients with stage III colon cancer.

Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide Therapy vs Other Donor Transplantations in Adults With Hematologic Cancers: A Systematic Review and Meta-analysis

Abstract Full Text
JAMA Oncol. Published online October 17, 2019. doi:10.1001/jamaoncol.2019.3541

This systematic review and meta-analysis assesses outcomes of stem cell transplantations using the haploidentical stem cell transplantation with posttransplant cyclophosphamide therapy compared with other mismatched or matched donor transplants in adult patients with hematologic cancers.

Research Letter

Association Between Aspirin Use and Biliary Tract Cancer Survival

Abstract Full Text
open access
JAMA Oncol. Published online October 17, 2019. doi:10.1001/jamaoncol.2019.4328

This database study analyzes the association between aspirin use and survival in patients with biliary tract cancer.

Viewpoint

A Cost-Focused Alternative Cancer Medication Dispensing Strategy—“Pack Splitting”

Abstract Full Text
JAMA Oncol. Published online October 17, 2019. doi:10.1001/jamaoncol.2019.4129

This Viewpoint argues that using a pack-splitting strategy for dispensing drugs that are sold in blister card packages can yield substantial cost savings for some expensive drugs.

Editorial

Is the Patient Cured?

Abstract Full Text
JAMA Oncol. Published online October 17, 2019. doi:10.1001/jamaoncol.2019.3612
Comment & Response

Correcting the Conclusion in a Study of Frameworks for Measurement of Absolute or Relative Clinical Survival Benefit

Abstract Full Text
JAMA Oncol. Published online October 17, 2019. doi:10.1001/jamaoncol.2019.4091

Correcting the Conclusion in a Study of Frameworks for Measurement of Absolute or Clinical Benefit—In Reply

Abstract Full Text
JAMA Oncol. Published online October 17, 2019. doi:10.1001/jamaoncol.2019.4132
October 10, 2019
Original Investigation

Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial

Abstract Full Text
JAMA Oncol. Published online October 10, 2019. doi:10.1001/jamaoncol.2019.3343

This phase 2 clinical trial examines the use of nivolumab combined with bevacizumab in treatment of women with relapsed platinum-sensitive or platinum-resistant ovarian cancer.

Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy: Subgroup Analyses of a Randomized Clinical Trial

Abstract Full Text
open access
JAMA Oncol. Published online October 10, 2019. doi:10.1001/jamaoncol.2019.3531

This subgroup analysis of a randomized clinical trial compares trifluridine/tipiracil treatment with placebo for progression-free and overall survival among patients with previously treated metastatic gastric or gastroesophageal junction cancer who had or had not undergone gastrectomy.

Cancer Care Chronicles

A Daily Struggle to Improve Kaplan-Meier Curves—Doctors on the Swing

Abstract Full Text
JAMA Oncol. Published online October 10, 2019. doi:10.1001/jamaoncol.2019.3549

In this essay, an oncologist’s describes how he uses the concept of positive deviance and Kaplan-Meier curves in face of treatment obstacles that seem insurmountable.

Comment & Response

Potential Areas of Interest in a Trial of Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin for Hepatocellular Carcinoma

Abstract Full Text
JAMA Oncol. Published online October 10, 2019. doi:10.1001/jamaoncol.2019.4052

Potential Areas of Interest in a Trial of Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin for Hepatocellular Carcinoma—In Reply

Abstract Full Text
JAMA Oncol. Published online October 10, 2019. doi:10.1001/jamaoncol.2019.4058
Correction

Error in Author’s Name

Abstract Full Text
free access
JAMA Oncol. Published online October 10, 2019. doi:10.1001/jamaoncol.2019.4781
October 3, 2019
Original Investigation

A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer

Abstract Full Text
open access has audio
JAMA Oncol. Published online October 3, 2019. doi:10.1001/jamaoncol.2019.3323

This cost-effectiveness microsimulation modeling study estimates incremental lifetime effects, costs, and cost-effectiveness of multigene testing of all patients with breast cancer compared with selective testing based on family history or clinical criteria.

Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced Pancreatic Cancer: A Phase 1b/2 Pilot Clinical Trial

Abstract Full Text
JAMA Oncol. Published online October 3, 2019. doi:10.1001/jamaoncol.2019.3394

This open-label, single-arm, pilot, phase 1b/2 clinical trial assesses outcomes following treatment with nab-paclitaxel plus gemcitabine plus the platinum-based cisplatin for patients with previously untreated metastatic pancreatic ductal adenocarcinoma.

Viewpoint

Broad Application of Multigene Panel Testing for Breast Cancer Susceptibility—Pandora’s Box Is Opening Wider

Abstract Full Text
JAMA Oncol. Published online October 3, 2019. doi:10.1001/jamaoncol.2019.4004

This Viewpoint argues that there is not yet enough evidence to support genetic testing in patients with breast cancer who do not meet current guidelines for testing.

Editorial

Crafting a JAMA Oncology Clinical Challenge

Abstract Full Text
free access
JAMA Oncol. Published online October 3, 2019. doi:10.1001/jamaoncol.2019.4001
Comment & Response

Immune-Related Adverse Events of Immune Checkpoint Inhibitors—From a Clinical to Pathophysiological View

Abstract Full Text
JAMA Oncol. Published online October 3, 2019. doi:10.1001/jamaoncol.2019.4049

Immune-Related Adverse Events of Immune Checkpoint Inhibitors—From a Clinical to Pathophysiological View—In Reply

Abstract Full Text
JAMA Oncol. Published online October 3, 2019. doi:10.1001/jamaoncol.2019.4055
×